Brexit is creating an uncertain time for all industries especially those which rely so heavily on relations with the EU – however regardless of the outcome, Parallel Imports of pharmaceuticals will continue.
The UK submitted the notification of its intention to withdraw from the European Union pursuant to Article 50 of the Treaty on European Union on 29 March 2017.
Until the UK leaves the EU or Article 50 is extended or revoked, the UK remains a full member of the EU and all the rights and obligations of EU membership remain in force.
If the UK leaves the EU without a deal (“no-deal”), regulation of medicines, medical devices and clinical trials will be affected.
Further information on Brexit can be found here.
Falsified Medicines Directive (FMD)
The deadline for the FMD has now passed (9 February 2019) and all affected companies should now be registered/on-boarded with SecurMed and/or the EMVO (European Medicines Verification Organisation). If you require more information or help with complying with the FMD, contact us today.
More information on the FMD can be found on these useful links: